INVESTOR INFORMATION

Investing in potentially the first cancer therapy to work in all tumours, irrespective of strain or mutation. 

LIfT Completed a major funding round in Jan 2022 and has a syndicate already being formed to take N-LIfT into the clinic for first-in-human trials in a range of solid tumours. If you are an institutional investor who would be interested in participating please email us

​

Proudly Supported by / Partnered with:

​

​

​

​

​

Merck kgaa logo.png
collaborate to Innovate logo.jpg
kizoo logo.png
EIT logo.png
BIA logo.png
Downing Ventures logo.png
KCL logo.png
meltwind logo.png

Note: This website contains certain statements that are not historical facts and may be forward-looking statements, please see our legal notices.

​

Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2022 LIfT BioSciences Ltd